Ghanta V K, Jones M T, Woodard D A, Durant J R, Hiramoto R N
Cancer Res. 1977 Mar;37(3):771-4.
Data are presented indicating marked antineoplastic activity for cis-dichlorodiammineplatinum(II) in MOPC 104E myeloma. One-eighteenth of the dose that produced 100% cures can be combined with noncurative, low doses of cyclophosphamide and 1,3-bis(2-chloroethyl)-1-nitrosourea to produce antineoplastic activity of the same degree as that produced by much higher dose regimens which regularly produce cures. Since, in the past, results of therapeutic trials in plasma cell tumors in humans have paralleled results in this animal model, clinical trials of cis-dichlorodiammineplatinum in multiple myeloma appear warranted.
数据表明，顺式二氯二氨铂（II）对MOPC 104E骨髓瘤具有显著的抗肿瘤活性。产生100%治愈率的剂量的十八分之一可与非治愈性低剂量的环磷酰胺和1,3-双（2-氯乙基）-1-亚硝基脲联合使用，以产生与通常能产生治愈效果的高得多的剂量方案相同程度的抗肿瘤活性。由于过去人类浆细胞肿瘤的治疗试验结果与该动物模型的结果相似，因此顺式二氯二氨铂在多发性骨髓瘤中的临床试验似乎是有必要的。
